Vaccination-Strategies

- · Active immunity produced by vaccine
- Immunity and immunologic memory similar to natural infection but without risk of disease.

General Rule:

The more similar a vaccine is to the disease-causing form of the organism, the better the immune response to the vaccine.

Classification of Vaccines

- Live attenuated
 - viral
 - bacterial
- Inactivated

Inactivated Vaccines

Whole

- viruses
- bacteria

Fractional

- · protein-based
 - toxoid
 - subunit
- polysaccharide-based
 - pure
 - conjugate

Live Attenuated Vaccines

- Attenuated (weakened) form of the "wild" virus or bacterium
- Must replicate to be effective
- Immune response similar to natural infection
- Usually effective with one dose*

*except those administered orally

Live Attenuated Vaccines

- Severe reactions possible
- Interference from circulating antibody
- Fragile must be stored and handled carefully

Live Attenuated Vaccines

Viral measles, mumps,

rubella, vaccinia, varicella/zoster,

yellow fever, rotavirus, intranasal influenza,

oral polio*

Bacterial BCG, oral typhoid

*not available in the United States

Inactivated Vaccines

- Cannot replicate
- Generally not as effective as live vaccines
- Less interference from circulating antibody than live vaccines
- Generally require 3-5 doses
- Immune response mostly humoral
- · Antibody titer may diminish with time

Inactivated Vaccines

Whole-cell vaccines

• Viral polio, hepatitis A,

rabies, influenza*

Bacterial pertussis*, typhoid*

cholera*, plague*

*not available in the United States

Inactivated Vaccines

Fractional vaccines

 Subunit hepatitis B, influenza, acellular pertussis, human papillomavirus, anthrax, Lyme*

• Toxoid diphtheria, tetanus

*not available in the United States

Pure Polysaccharide Vaccines

- Not consistently immunogenic in children younger than 2 years of age
- No booster response
- Antibody with less functional activity
- Immunogenicity improved by conjugation

Polysaccharide Vaccines

Pure polysaccharide

- pneumococcal
- meningococcal
- Salmonella Typhi (Vi)

Conjugate polysaccharide

- Haemophilus influenzae type b
- pneumococcal
- meningococcal

Type of Vaccines by route of administration

Type of	Bacterial	Viral						
Administration								
Intramuscular	Diphtheria	Hepatitis A						
	Tetanus	Hepatitis B						
	Pertussis (whole	Haemophilus influenzae b						
	cell)	Most Flu						
	Acellular Pertussis	Rabies						
	Plague							
	Pneumococcal							
	Typhoid Vi							
Subcutaneous	Anthrax	Japanese Encephalitis Virus						
	Meningococcal	Measles						
	Pneu mococcal	Mumps						
		Rubella						
		Polio (IPV)						
		Varicella						
		Yellow Fever						
Intradermal	BCG	Vaccinia (Smallpox)						
		Rabies (HDCV for pre -exposure						
		vaccine)						
Inhaled		FluMist						
Oral	Rotavirus	Polio (OPV)						
	Ty21a	, ,						

Principles of Vaccination

General Rule

Inactivated vaccines are generally not affected by circulating antibody to the antigen.

Live attenuated vaccines may be affected by circulating antibody to the antigen.

Intervals and Ages

 Vaccine doses should not be administered at intervals less than the minimum intervals or earlier than the minimum age

Vaccination doesn't count

 It is not necessary to restart the series or add doses because of an extended interval between doses

Vaccination counts

Vaccine Adverse Reactions

Local

pain, swelling, redness at site of injection common with inactivated vaccines usually mild and self-limited

Systemic

fever, malaise, headache nonspecific may be unrelated to vaccine

Contraindications and Precautions

Contraindication:

 A condition in a recipient that greatly increases the chance of a serious adverse reaction.

Precaution:

- A condition in a recipient that might increase the chance or severity of an adverse reaction, or
- Might compromise the ability of the vaccine to produce immunity

Contraindications and Precautions

Permanent contraindications to vaccination:

- severe allergic reaction to a vaccine component or following a prior dose
- encephalopathy not due to another identifiable cause occurring within 7 days of pertussis vaccination

Vaccination of Pregnant Women

- Live vaccines should not be administered to women known to be pregnant
- In general inactivated vaccines may be administered to pregnant women for whom they are indicated

Vaccination of Immunosuppressed Persons

- Live vaccines should not be administered to severely immunosuppressed persons
- Inactivated vaccines are safe to use in immunosuppressed persons but the response to the vaccine may be decreased

Invalid Contraindications to Vaccination

- Mild illness
- Antimicrobial therapy
- Disease exposure or convalescence
- Pregnant or immunosuppressed person in the household
- Breastfeeding
- Preterm birth
- Allergy to products not present in vaccine or allergy that is not anaphylactic
- Family history of adverse events
- Tuberculin skin testing
- Multiple vaccines

Vaccination During Acute Illness

- No evidence that acute illness reduces vaccine efficacy or increases vaccine adverse reactions
- Vaccines should be delayed until the illness has improved
- Mild illness, such as otitis media or an upper respiratory infection, is NOT a contraindication to vaccination

What is in a vaccine?

Vaccines have :

- Antigenic material (live attenuated, killed etc.
- Stabilizers (mono soduim glutamate, 2-phenoxy ethanol)
- Adjuvants (increase immune response)
- Preservatives (prevent fungal and bacterial growth)
 (e.g anitbiotics, formaldehyde and thimerosal)

Thimerosal

Organic mercury has antifungal and antibacterial properties.

Used in multidose vials to prevent contamination

Not needed in more expensive single dose vaccines.

No convincing evidence that thiomersal is a factor in the onset of autism?

Currently not used for recommended childhood vaccines

Adjuvant

- Substances that enhance the immune response
- Two categories:
 - vehicles
 - immunomodulators

Adjuvants functioning as vehicles I

- Human use:
 - Alum compounds
 - · Aluminum hydroxide and phosphate
 - the only licensed adjuvants in U.S.
 - MF59
 - · Oil and water emulsion
 - Marketed in Europe

Adjuvants functioning as vehicles cont.

- Animal use:
 - Freund's Complete Adjuvant (CFA)
 - desiccated Mycobacterium butyricum, mineral oil and an emulsifying agent, mannide monooleate
 - causes potentially severe local inflammatory lesions, chronic granulomas, abscesses, and tissue sloughs.
 Injected into the murine footpad, it can cause chronic lameness and arthritis; injected intraperitoneally, it can cause peritonitis
 - Freund's Incomplete Adjuvant
 - Mineral oil and Mannide monooleate
 - · Fewer side effects, adequate for boosting

Immunomodulatory Adjuvants

- Purified Protein Derivative (PPD)
- Lipopolysaccharide (LPS; bacterial endotoxin)
- Lipid A lipid portion of LPS
- · Cholera toxin B subunit
- CpG

Immunization schedule for children

Recommended Immunization Schedule for Persons Aged 0–6 Years—UNITED STATES • 2008

For those who fall behind or start late, see the catch-up schedule

Vaccine ▼ Age ►						12 months			19–23 months		4–6 years	
Hepatitis B ¹	НерВ	НерВ		see footnote1		He	HepB		*		# 4 9 9 9 8	
Rotavirus ²	7 7 8 8		Rota	Rota	Rota				* * * * * * * * * * * * * * * * * * *	7		Rar rec
Diphtheria, Tetanus, Pertussis³	# # # # # # # # # # # # # # # # # # #		DTaP	DTaP	DTaP	see footnote3		ГаР		* * * * * * * * * * * * * * * * * * *	DTaP	age
Haemophilus influenzae type b⁴	**************************************		Hib	Hib	Hib¹		ib	**************************************	# * * * * * * * * * * * * * * * * * * *	* * * * * * * * * * * * * * * * * * *		
Pneumococcal ⁵	81137-0-71037-107-0-5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		PCV	PCV	PCV	PC	v		**************************************		PV	Cer high
Inactivated Poliovirus			IPV	IPV	IPV		,	**************************************		IPV	grou	
Influenza [§]	**************************************			0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Influenza (Yearly)							
Measles, Mumps, Rubella ⁷	T49240340344034034		 	0 h 4 0 h 4	DATOLAGORATORIONATI F F B C C C C C C C C C C C C C C C C C		MR		93109400103419340 0 0 0 0 0 0 0 0 0 0	7 2 3 4 5 6 6 7 7 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	MMR	
Varicella ⁸	# 1430 (0740) # 400 100		0004 100F 00E 07U 1				cella	> + + + + + + + + + + + + + + + + +	97101210171017111710 0 0 0 0 0 0 0 0 0 0 0 0 0	### > P # # > P # * P #	Varicella	
Hepatitis A ⁹	# # # # # # # # # # # # # # # # # # #		• • • • • • • • • • • • • • • • • • •		PT		НерА (2 doses) !	НерА	Series	
Meningococcal ¹⁰				**************************************			0 0 0 0 0 0 0 0 0 0		**************************************	М	CV4	